News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Trevi Therapeutics Announces The Issuance Of Two Patents Covering The Oral Sustained Release Formulation Of Nalbuphine ER



8/14/2014 8:05:09 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW HAVEN, Conn.--(BUSINESS WIRE)--Trevi Therapeutics, Inc. (“Trevi”), a clinical stage biotechnology company developing Nalbuphine ER for chronic pruritus conditions, today announced that it has received two issued U.S. patents with claims protecting the oral sustained release formulation of nalbuphine. The patent numbers are 8,771,732 and 8,765,175.

The Company believes that both of these patents will be Orange Book-listable. These two patents complement two additional issued formulation patents, as well as an issued patent protecting the method of use of Nalbuphine ER in the “Methods for Treatment of Pruritus,” which expires in December 2032. Trevi continues to prosecute additional claims to further enhance its existing patent estate protecting Nalbuphine ER in itch.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES